Compile Data Set for Download or QSAR
Report error Found 81 Enz. Inhib. hit(s) with all data for entry = 9911
TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160878(US9107923, 48 | US10093655, Example 48 | US1101490...)
Affinity DataKi:  0.571nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160912(US9107923, 1 | US9107923, 2 | US10093655, Example ...)
Affinity DataKi:  3.11nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160861(US9107923, 31 | US10093655, Example 31 | US1101490...)
Affinity DataKi:  3.61nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160894(US9107923, 64 | US10093655, Example 64 | US1101490...)
Affinity DataKi:  4.17nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160871(US9107923, 41 | US10093655, Example 41 | US1101490...)
Affinity DataKi:  5.41nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160875(US9107923, 45 | US10093655, Example 45 | US1101490...)
Affinity DataKi:  6.91nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160876(US9107923, 46 | US10093655, Example 46 | US1101490...)
Affinity DataKi:  7.66nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160867(US9107923, 37 | US10093655, Example 37 | US1101490...)
Affinity DataKi:  8.42nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160918(US9107923, 7 | US9107923, 8 | US11014909, Example ...)
Affinity DataKi:  8.54nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160884(US9107923, 54 | US9107923, 55 | US10093655, Exampl...)
Affinity DataKi:  9.33nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160873(US9107923, 43 | US10093655, Example 43 | US1101490...)
Affinity DataKi:  9.65nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160880(US9107923, 50 | US10093655, Example 50 | US1101490...)
Affinity DataKi:  10.1nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160922(US11014909, Example 11 | BDBM289101 | US9107923, 1...)
Affinity DataKi:  10.9nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160892(US9107923, 62 | US10093655, Example 62 | US1101490...)
Affinity DataKi:  12.1nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160930(US9107923, 19 | US11014909, Example 19)
Affinity DataKi:  12.9nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160893(US9107923, 63 | US10093655, Example 63 | US1101490...)
Affinity DataKi:  13.4nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160869(US9107923, 39 | US10093655, Example 39 | US1101490...)
Affinity DataKi:  15nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160912(US9107923, 1 | US9107923, 2 | US10093655, Example ...)
Affinity DataKi:  15.3nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160898(US9107923, 68 | US10093655, Example 68 | US1101490...)
Affinity DataKi:  16.9nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160925(US9107923, 14 | US9107923, 15 | US11014909, Exampl...)
Affinity DataKi:  17.5nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160875(US9107923, 45 | US10093655, Example 45 | US1101490...)
Affinity DataKi:  18.6nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160918(US9107923, 7 | US9107923, 8 | US11014909, Example ...)
Affinity DataKi:  21nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160891(US9107923, 61 | US10093655, Example 61 | US1101490...)
Affinity DataKi:  23.8nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160884(US9107923, 54 | US9107923, 55 | US10093655, Exampl...)
Affinity DataKi:  24.2nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160895(US9107923, 65 | US10093655, Example 66 | US1101490...)
Affinity DataKi:  26.9nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160887(US9107923, 57 | US10093655, Example 57 | US1101490...)
Affinity DataKi:  30.5nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160868(US9107923, 38 | US10093655, Example 38 | US1101490...)
Affinity DataKi:  31.1nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160908(US9107923, 78 | US10093655, Example 78 | US1101490...)
Affinity DataKi:  32.3nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160917(US9107923, 6 | US11014909, Example 6)
Affinity DataKi:  33.1nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160895(US9107923, 65 | US10093655, Example 66 | US1101490...)
Affinity DataKi:  34.4nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160929(US9107923, 18 | US11014909, Example 18)
Affinity DataKi:  35.7nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160857(US9107923, 27 | US10093655, Example 27 | US1101490...)
Affinity DataKi:  36.2nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160899(US9107923, 69 | US10093655, Example 69 | US1101490...)
Affinity DataKi:  38.3nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160855(US9107923, 25 | US10093655, Example 25 | US1101490...)
Affinity DataKi:  38.5nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160914(US9107923, 3 | US9107923, 4 | US10093655, Example ...)
Affinity DataKi:  40.6nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160903(US9107923, 73 | US10093655, Example 73 | US1101490...)
Affinity DataKi:  43.4nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160927(US9107923, 16 | US9107923, 17 | US11014909, Exampl...)
Affinity DataKi:  44.3nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM498196(2-[4-(3,5-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyr...)
Affinity DataKi:  45.9nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM498193(6-{4-[(3-ethylpyridin-2-yl)oxy]-2-methylphenyl}-1,...)
Affinity DataKi:  52.7nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160925(US9107923, 14 | US9107923, 15 | US11014909, Exampl...)
Affinity DataKi:  54.7nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160923(US9107923, 12 | US11014909, Example 12)
Affinity DataKi:  55.1nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160911(US9107923, 81 | US10093655, Example 81 | US1101490...)
Affinity DataKi:  58nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160916(US9107923, 5 | US11014909, Example 5)
Affinity DataKi:  58nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160927(US9107923, 16 | US9107923, 17 | US11014909, Exampl...)
Affinity DataKi:  59.1nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160882(US9107923, 52 | US10093655, Example 52 | US1101490...)
Affinity DataKi:  63.1nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160877(US9107923, 47 | US10093655, Example 47 | US1101490...)
Affinity DataKi:  82.3nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160920(US9107923, 9 | US9107923, 10 | US11014909, Example...)
Affinity DataKi:  82.3nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160870(US9107923, 40 | US10093655, Example 40 | US1101490...)
Affinity DataKi:  82.7nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160852(US9107923, 22 | US10093655, Example 22 | US1101490...)
Affinity DataKi:  82.7nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Pfizer

US Patent
LigandPNGBDBM160888(US9107923, 58 | US10093655, Example 58 | US1101490...)
Affinity DataKi:  86.2nMAssay Description:D1 binding assays were performed using over-expressing LTK human cell lines. To determine basic assay parameters, ligand concentrations were determin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 81 total ) | Next | Last >>
Jump to: